Latest Vico Therapeutics News & Updates

See the latest news and media coverage for Vico Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Vico Therapeutics

Neurology genetic medicine company developing RNA-based therapies

vicotx.com
Headquarters
Leiden, Netherlands
Founded year
2019
Company type
Private company
Number of employees
49–50

Last updated

Latest news about Vico Therapeutics

In short: Vico Therapeutics started twice-yearly VO659 dosing in a Phase I/IIa trial cohort.

Company announcements

Vico Therapeutics

Vico Therapeutics reports positive VO659 Phase 1/2a data

VO659 reduces cerebrospinal fluid mutant huntingtin by 28% at day 85 in Huntington’s disease patients, with no sustained neurofilament light chain increase and generally good tolerability.

Vico Therapeutics

Vico Therapeutics raises $60M Series B financing

Led by Ackermans & van Haaren, funds advance VO659's Phase 1/2a trial in SCA3, SCA1 and Huntington's disease and pipeline expansion. Jeroen Vangindertael joins the board.

Vico Therapeutics

Vico Therapeutics doses first patient in VO659 Phase 1/2a trial

The trial evaluates VO659 in Huntington's disease and spinocerebellar ataxia types 1 and 3, expecting to enroll about 71 participants.

Unlock all announcements with a

Media coverage

Business Wire

Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)

DUBLIN & PARIS--(BUSINESS WIRE)--Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key...

Unlock all articles with a

Never miss news about Vico Therapeutics

Track Vico Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.